<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mol. Biosci.</journal-id>
<journal-title>Frontiers in Molecular Biosciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mol. Biosci.</abbrev-journal-title>
<issn pub-type="epub">2296-889X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">678444</article-id>
<article-id pub-id-type="doi">10.3389/fmolb.2021.678444</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Molecular Biosciences</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Quantitative Proteomics Analysis of FFPE Tumor Samples Reveals the Influences of NET-1 siRNA Nanoparticles and Sonodynamic Therapy on Tetraspanin Protein Involved in HCC</article-title>
<alt-title alt-title-type="left-running-head">Wu et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Nanoparticles and Sonodynamic in HCC</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Bolin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shang</surname>
<given-names>Haitao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Jiayin</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liang</surname>
<given-names>Xitian</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yuan</surname>
<given-names>Yanchi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Yichi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Chunyue</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jing</surname>
<given-names>Hui</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cheng</surname>
<given-names>Wen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1050784/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Department of Ultrasound, Harbin Medical University Cancer Hospital, <addr-line>Harbin</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>Department of Interventional Ultrasound, Harbin Medical University Cancer Hospital, <addr-line>Harbin</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<label>
<sup>3</sup>
</label>Institute of Cancer Prevention and Treatment, Heilongjiang Academy of Medical Science, Harbin Medical University, <addr-line>Harbin</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<label>
<sup>4</sup>
</label>Department of Radiation Oncology, Harbin Medical University Cancer Hospital, <addr-line>Harbin</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/334396/overview">Elisa Araldi</ext-link>, ETH Z&#xfc;rich, Switzerland</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/923939/overview">Marya Ahmed</ext-link>, University of Prince Edward Island, Canada</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/128968/overview">Maria Ada Malvindi</ext-link>, HiQ-Nano srl, Italy</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Wen Cheng, <email>chengwen@hrbmu.edu.cn</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Nanobiotechnology, a section of the journal Frontiers in Molecular Biosciences</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>10</day>
<month>05</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>8</volume>
<elocation-id>678444</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>03</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>04</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Wu, Shang, Liu, Liang, Yuan, Chen, Wang, Jing and Cheng.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Wu, Shang, Liu, Liang, Yuan, Chen, Wang, Jing and Cheng</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Hepatocellular carcinoma (HCC) poses a severe threat to human health. The NET-1 protein has been proved to be strongly associated with HCC proliferation and metastasis in our previous study. Here, we established and validated the NET-1 siRNA nanoparticles system to conduct targeted gene therapy of HCC xenograft <italic>in vivo</italic> with the aid of sonodynamic therapy. Then, we conducted a label-free proteome mass spectrometry workflow to analyze formalin-fixed and paraffin-embedded HCC xenograft samples collected in this study. The result showed that 78 proteins were differentially expressed after NET-1 protein inhibited. Among them, the expression of 17 proteins upregulated and the expression of 61 proteins were significantly downregulated. Of the protein abundance, the vast majority of Gene Ontology enrichment terms belong to the biological process. The KEGG pathway enrichment analysis showed that the 78 differentially expressed proteins significantly enriched in 45 pathways. We concluded that the function of the NET-1 gene is not only to regulate HCC but also to participate in a variety of biochemical metabolic pathways in the human body. Furthermore, the protein&#x2013;protein interaction analysis indicated that the interactions of differentially expressed proteins are incredibly sophisticated. All the protein&#x2013;protein interactions happened after the NET-1 gene has been silenced. Finally, our study also provides a useful proposal for targeted therapy based on tetraspanin proteins to treat HCC, and further mechanism investigations are needed to reveal a more detailed mechanism of action for NET-1 protein regulation of&#x20;HCC.</p>
</abstract>
<kwd-group>
<kwd>hepatocellular carcinoma</kwd>
<kwd>sonodynamic therapy</kwd>
<kwd>tetraspanin protein</kwd>
<kwd>mass spectrometry</kwd>
<kwd>proteomics</kwd>
<kwd>ultrasound</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Worldwide, liver cancer is the fourth most common cause of cancer-related death and ranks sixth in terms of incident cases (<xref ref-type="bibr" rid="B36">Villanueva, 2019</xref>). With a 5-year survival of 18%, liver cancer is the second most lethal tumor after pancreatic cancer. Hepatocellular carcinoma is a major type of primary liver cancer. Changes in protein expression accompany HCC progress; thus, some proteins can be used as potential biomarkers for diagnosis and treatment (<xref ref-type="bibr" rid="B9">Ferrin et&#x20;al., 2015</xref>).</p>
<p>In 1989, Prof. Yumita first reported sonodynamic therapy (SDT) (<xref ref-type="bibr" rid="B45">Yumita et&#x20;al., 1989</xref>), which is based on the photodynamic therapy (PDT). This noninvasive treatment technology has already been known as a new anticancer strategy which uses nonthermal ultrasound energy in combination with sonosensitizer agents (<xref ref-type="bibr" rid="B4">Brown et&#x20;al., 2004</xref>; <xref ref-type="bibr" rid="B5">Castano et&#x20;al., 2004</xref>; <xref ref-type="bibr" rid="B27">Rosenthal et&#x20;al., 2004</xref>; <xref ref-type="bibr" rid="B23">McHale et&#x20;al., 2016</xref>). Normally, low-intensity focused ultrasound (LIFU, 1&#x2013;3&#xa0;MHz) frequency is used for this treatment technology to enhance the cavitation effect (<xref ref-type="bibr" rid="B34">Tachibana et&#x20;al., 2008</xref>; <xref ref-type="bibr" rid="B32">Shibaguchi et&#x20;al., 2011</xref>). The sonosensitizer agents together with ultrasound irradiation generate reactive oxygen species (ROS) that could induce cancer cell death under aerobic conditions (<xref ref-type="bibr" rid="B46">Yumita et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B47">Yumita et&#x20;al., 2012</xref>).</p>
<p>Several reports have revealed that LIFU is able to enhance the anticancer effect of some chemotherapeutic drugs and improve cell membrane permeability. Our previous research studies have proved that the combination of LIFU irradiation and nanobubble system is regarded as an efficient and safe method for gene transfection (<xref ref-type="bibr" rid="B42">Wu et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B41">Wu et&#x20;al., 2019</xref>). Besides, LIFU-combined NET-1 siRNA conjugated nanobubble system could effectively inhibit tumor growth and prolong the life of experimental animals (<xref ref-type="bibr" rid="B29">Shang et&#x20;al., 2019</xref>).</p>
<p>Neuroepithelial transforming gene 1 (NET-1) is located at chromosome 10p15 and encodes a 54&#x2002;kDa oncoprotein (<xref ref-type="bibr" rid="B7">Chan et&#x20;al., 1996</xref>). It is a guanine nucleotide exchange factor involved in cytoskeletal regulation and cancer cell invasion (<xref ref-type="bibr" rid="B26">Murray et&#x20;al., 2008</xref>). All NET genes have initially been identified as EST clones with sequences homologous to tetraspan, a superfamily which is distinguished by the presence of four transmembrane domains and has been implicated in signal transduction, cell adhesion, migration, proliferation, and differentiation (<xref ref-type="bibr" rid="B28">Serru et&#x20;al., 2000</xref>; <xref ref-type="bibr" rid="B17">Kanetaka et&#x20;al., 2001</xref>). NET-1 protein was known to be a member of the tetraspanin family (<xref ref-type="bibr" rid="B44">Ye et&#x20;al., 2010</xref>). NET-1 protein has been identified in HCC, where it is a mediator of invasion and metastasis (<xref ref-type="bibr" rid="B8">Chen et&#x20;al., 2007</xref>; <xref ref-type="bibr" rid="B30">Shen et&#x20;al., 2008</xref>; <xref ref-type="bibr" rid="B39">Wu et&#x20;al., 2013</xref>). Our previous research proved that the NET-1 protein had an impactful role in the proliferation and stiffness of HCC (<xref ref-type="bibr" rid="B29">Shang et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B41">Wu et&#x20;al., 2019</xref>). Besides, the low expression of NET-1 protein also reduced the migration and invasive ability of HCC (<xref ref-type="bibr" rid="B40">Wu et&#x20;al., 2016</xref>). However, the potential carcinogenic mechanism of NET-1 protein is still unclear.</p>
<p>Proteomics is an efficient research tool to reveal the mechanism and pathogeny of diseases on the proteinic level. Because of proteomics, analysis could analyze quite a lot of expressed proteins in tissues or cells; this revolutionary technology has been applied to identify HCC-related proteins in many studies (<xref ref-type="bibr" rid="B6">Chaerkady et&#x20;al., 2008</xref>; <xref ref-type="bibr" rid="B43">Yang et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B12">Gao et&#x20;al., 2019</xref>). However, altered expression of proteins quantified with conventional label-free proteomic methods was limited by the fresh or rapidly frozen tissue samples. Most human tumor samples archived in hospitals for pathologic diagnosis are formalin-fixed paraffin-embedded (FFPE), which have been widely used in the long-term preservation of tissues and organs (<xref ref-type="bibr" rid="B1">Bass et&#x20;al., 2014</xref>). Besides, multifarious prescient technologies have been invented for transcriptomic (<xref ref-type="bibr" rid="B18">Li et&#x20;al., 2014</xref>), genomic (<xref ref-type="bibr" rid="B20">Martelotto et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B35">Van Allen et&#x20;al., 2014</xref>), proteomic, and protein (<xref ref-type="bibr" rid="B19">Mantsiou et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B15">Iglesias-Gato et&#x20;al., 2016</xref>) from FFPE samples. In 1991, FFPE tissues have been analyzed for protein using antibodies as the invention of the heat-induced antigen retrieval (HIAR) technique for immunohistochemistry (IHC) (<xref ref-type="bibr" rid="B31">Shi et&#x20;al., 1991</xref>). Afterward, kinds of different technologies have been applied to extract proteins from FFPE samples, which have extended the research of proteins to a proteomic level (<xref ref-type="bibr" rid="B10">Fowler et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B37">Wakabayashi et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B3">Broeckx et&#x20;al., 2016</xref>). These studies have initially confirmed that FFPE samples can be used in mass spectrometry&#x2013;based proteomic analysis.</p>
<p>Here, we established and validated the NET-1 siRNA nanoparticles system, which was then utilized for targeted gene delivery of HCC xenograft <italic>in vivo</italic> with the aid of SDT. Then, proteomic analyses of FFPE HCC xenograft samples were conducted to characterize the global quantitative protein expression profile and identify the differential protein expressions after gene therapy. Furthermore, we aimed to shed light on the functions of tetraspanin protein involved in HCC development and reveal the HCC-related proteins valuable for targeted therapy.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Preparation of Neuroepithelial Transforming Gene 1 siRNA Nanoparticles</title>
<p>The NET-1 siRNA duplex and the negative control duplex (NC-siRNA) were designed according to our previous research (<xref ref-type="bibr" rid="B41">Wu et&#x20;al., 2019</xref>). The nanoparticles were prepared with DSPG, DSPC, and DSPE-PEG2000, and the weight ratio was 7:2:1. All the phospholipids were purchased from Avanti Polar Lipids (Avanti Polar Lipids, Alabaster, AL, United&#x20;States). 20&#x2002;mg of phospholipids were dissolved in a mixed solution of chloroform and methyl alcohol. The mixed solution was subsequently purged by vacuum rotary evaporation to form phospholipid thin film. Then, the thin film was hydrated at 40&#xb0;C with 5&#xa0;ml of DEPC-treated H<sub>2</sub>O. This was followed by dissolving the appropriate amounts of NET-1 siRNA duplex in the lipid film solution. The NET-1 siRNA nanoparticles and NC-siRNA duplex nanoparticles were obtained using an extrusion technology by mini-extruders (Avanti Polar Lipids, Alabaster, AL, United&#x20;States) through a 400&#xa0;nm membrane for 11 times. The obtained NET-1 siRNA nanoparticles and NC-siRNA duplex nanoparticles were then transferred into a sealed vial and stored at 4&#xb0;C for further experiments.</p>
<p>The structure of NET-1 siRNA nanoparticles was detected under transmission electron microscope (TEM, Hitachi TEM system, Japan). The size and zeta potential were investigated by dynamic light scattering (DLS) via the Malvern Zetasizer Nanoseries (Zeta PALS BI-90 Plus, Brookhaven Instruments).</p>
</sec>
<sec id="s2-2">
<title>Cell Lines and Animal Tumor Inoculation</title>
<p>The human HCC cell line HepG2 cells were a generous gift from the Institute of Cancer Research affiliated with Harbin Medical University (Harbin, China). Cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in a humidified atmosphere containing 5% CO<sub>2</sub>/95% air at 37&#xb0;C.</p>
<p>BALB/c nude female mice (6&#x2013;8&#xa0;weeks, 10&#x2013;25&#xa0;g) were purchased from Beijing Vital River Laboratory Animal Technology (Beijing, China). All the animals were housed in an environment with a temperature of 22&#x20;&#xb1; 1&#xb0;C, a relative humidity of 50&#x20;&#xb1; 1%, and a light/dark cycle of 12:12&#xa0;h. All animal studies (including the mice euthanasia procedure) were done in compliance with the regulations and guidelines of Harbin Medical University institutional animal care and conducted according to the Association for Assessment and Accreditation of Laboratory Animal Care and the Institutional Animal Care and Use Committee guidelines. Mice were anesthetized with 3% isoflurane inhalation and 1&#xa0;L/min 100% oxygen. A total of 5&#x20;&#xd7; 10<sup>6</sup> HepG2 cells were suspended in 50&#xa0;ml PBS and 50&#xa0;ml Matrigel (BD Biosciences, San Jose, CA, United&#x20;States). Tumor cell&#x2013;Matrigel mixture (100&#xa0;&#xb5;l) was subcutaneously injected in the right back position of the&#x20;mice.</p>
</sec>
<sec id="s2-3">
<title>
<italic>In vivo</italic> Studies</title>
<p>Once the tumor diameter reached 0.5&#xa0;cm, the mice bearing tumors were randomly divided into five groups (six mice/group): group A, blank (PBS); group B, NET-1 siRNA nanoparticles without LIFU irradiation; group C, NET-1 siRNA nanoparticles with LIFU irradiation; group D, NC-siRNA duplex nanoparticles with LIFU irradiation; and group E, blank nanoparticles with LIFU irradiation. All the treatment nanoparticles were intravenously administered via the tail vein at a dose of 5&#xa0;ml/kg body weight.</p>
<p>At 30&#xa0;min postinjection, all groups were irradiated with LIFU using a CGZZ low-frequency ultrasound treatment instrument (Institute of Ultrasound Imaging, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China). LIFU parameters were as follows: frequency of 1&#xa0;MHz, pulse repetition frequency of 1&#xa0;kHz, duty cycle yield of 50%, intensity of 1.0&#xa0;W/cm<sup>2</sup>, and duration of irradiation of 5&#xa0;min per mouse. The nude mice were treated twice a week for a total of 60&#xa0;days. The survival end point was a tumor diameter of 20&#xa0;mm in any direction (according to the guidelines for Tumor Induction in Mice and Rats, American Association for Laboratory Animal Science, Memphis, TN, United&#x20;States); the maximum tumor diameter was measured twice every week using Aixplorer United&#x20;States system with high-frequency probe (Super Linear TM SL15-4, Super Sonic Imagine, Aix-en-Provence, France). The HCC xenograft samples were harvested after euthanasia and formalin-fixed and paraffin-embedded for long-stem storage and further analyses.</p>
</sec>
<sec id="s2-4">
<title>Immunohistochemical Staining</title>
<p>Half of the FFPE tumor samples were sectioned 4.5&#xa0;&#x3bc;m thick and incubated 10&#xa0;min with 0.3% H<sub>2</sub>O<sub>2</sub> to block endogenous peroxidase. The sections were incubated overnight at 4&#xb0;C with primary mouse antihuman NET-1 antibody (1:100, Abcam, Cambridge, United&#x20;Kingdom) and then with secondary antibody at 37&#xb0;C for 30&#xa0;min. The sections were then stained with 3,3&#x2032;-diaminobenzidine and were counterstained with hematoxylin, dehydrated in alcohol, and mounted. Quantitative analysis of total image staining was carried out by ImageJ software (v.1.80; National Institutes of Health, Bethesda, MD, United&#x20;States).</p>
</sec>
<sec id="s2-5">
<title>Proteomic Analysis</title>
<sec id="s2-5-1">
<title>Total Protein Extraction</title>
<p>The rest of FFPE HCC xenograft samples in group A and group C were selected for proteomic analysis. The FFPE samples were dewaxed with octane and then hydrated with graded ethanol. After hydration, the sample was washed twice with PBS. After removing the PBS solution, an appropriate amount of protein lysate (4% SDS, 100&#xa0;mM Tris, pH &#x3d; 8.5) was added and incubated at 95&#xb0;C for 10&#xa0;min at room temperature, mixed by shaking and sonicated in an ice-water bath for 5&#xa0;min. The samples were de-crosslinked with a refractive index at 95&#xb0;C for 60&#xa0;min and then reduced by adding an appropriate amount of TCEP and carboxyamidomethylated in CAA at 95&#xb0;C for 5&#xa0;min. The samples were sequentially centrifuged at 12,000<italic>g</italic> at 4&#xb0;C for 15&#xa0;min. Collecting the supernatant and adding four times the volume of precooling acetone at &#x2212;20&#xb0;C and precipitated it at &#x2212;20&#xb0;C for at least 4&#xa0;h. Centrifuging at 12,000<italic>g</italic> for 15&#xa0;min at 4&#xb0;C. Collect the precipitate and air drying. An appropriate amount of protein solution (6&#xa0;M urea, 100&#xa0;mM TEAB, pH &#x3d; 8.5) was added to dissolve the protein pellet.</p>
</sec>
<sec id="s2-5-2">
<title>Trypsin Treatment</title>
<p>The protein solution was added to flat membrane ultrafiltration (cut off molecular is 10&#xa0;kDa) tube and was centrifuged at 14,000<italic>g</italic> at room temperature for 20&#xa0;min, and the flow-through was discarded. 100&#xa0;&#x3bc;l of 50&#xa0;mM TEAB was added, and the sample was centrifuged at 14,000<italic>g</italic> at room temperature for 20&#xa0;min. The washing procedure was repeated four times. 100&#xa0;&#x3bc;l of 50&#xa0;mM TEAB and an amount of 1:50 mass ratio of trypsin was added to the protein and incubated at 37&#xb0;C overnight. After being centrifuged at 14,000<italic>g</italic> for 20&#xa0;min, an equal volume of 2% formic acid was added. After mixing, the solution was centrifuged at 14,000<italic>g</italic> for 20&#xa0;min at room temperature. The supernatant of flow-through was slowly passed through a C18 desalting column, and then, 1&#xa0;ml washing solution (0.1% formic acid and 4% acetonitrile) was added to wash three times in succession, then 0.4&#xa0;ml of eluent (0.1% formic acid and 75% acetonitrile) was added to elute twice in sequence, and the eluent samples were combined and freeze-dried.</p>
</sec>
</sec>
<sec id="s2-6">
<title>Liquid Chromatography&#x2013;Mass Spectrometry/Mass Spectrometry Analysis</title>
<p>Mobile phase A (100% water and 0.1% formic acid) and B solution (80% acetonitrile and 0.1% formic acid) were prepared. The lyophilized powder was dissolved in 10&#xa0;&#x3bc;l of solution A, centrifuged at 15,000&#xa0;rpm for 20&#xa0;min at 4&#xb0;C, and 1&#xa0;&#x3bc;g of the supernatant was injected into a homemade C18&#x20;Nano-Trap column (2&#xa0;cm &#xd7; 75&#xa0;&#x3bc;m, 3&#xa0;&#x3bc;m). Peptides were separated in a homemade analytical column (15&#xa0;cm &#xd7; 150&#xa0;&#x3bc;m, 1.9&#xa0;&#x3bc;m) using linear gradient elution, as listed in <xref ref-type="sec" rid="s10">Supplementary Table S1</xref>. The isolated peptides were analyzed by the Q Exactive series mass spectrometer (Thermo Fisher), with ion source of Nanospray Flex&#x2122; (ESI), spray voltage of 2.3&#xa0;kV, and ion transport capillary temperature of 320&#xb0;C. Full scan ranges from m/z 350 to 1,500 with resolution of 60,000 (at m/z 200), an automatic gain control (AGC) target value was 3&#x20;&#xd7; 10&#x20;6, and a maximum ion injection time was 20&#xa0;ms. The top 20 (<xref ref-type="bibr" rid="B14">Huang et&#x20;al., 2009</xref>) precursors of the highest abundant in the full scan were selected and fragmented by higher-energy collisional dissociation (HCD) and analyzed in MS/MS, where resolution was 15,000 (at m/z 200), the automatic gain control (AGC) target value was 5&#x20;&#xd7; 10<sup>4</sup>, the maximum ion injection time was 45&#xa0;ms, a normalized collision energy was set as 27%, and intensity threshold was 2.2 &#xd7; 10<sup>4</sup>. The dynamic exclusion parameter was 20&#xa0;s. The raw data of M.S. detection were named as &#x201c;raw.&#x201d;</p>
</sec>
<sec id="s2-7">
<title>Data Analysis</title>
<sec id="s2-7-1">
<title>The Identification and Quantitation of Protein</title>
<p>The resulting spectra from each fraction were searched separately against the Homo sapiens UniProt database by the search engines: Proteome Discoverer 2.2 (PD 2.2, Thermo). The search parameters are set as follows: mass tolerance for precursor ion was ten ppm and mass tolerance for production was 0.02&#xa0;Da. Carbamidomethyl was specified in PD 2.2 as fixed modifications. Oxidation of methionine (M) and acetylation of the N-terminus was specified in PD 2.2 as variable modifications. A maximum of 2 missed cleavage sites was allowed.</p>
<p>The identified protein contains at least one unique peptide with FDR no more than 1.0%. Proteins containing similar peptides that could not be distinguished by MS/MS analysis were identified as the same protein group. Precursor ion was quantified by a label-free quantification method based on intensity. Mann&#x2013;Whitney Test statistically analyzed the protein quantitation results for proteins whose quantitation significantly different between experimental and control groups were defined as differentially expressed proteins (DEP).</p>
</sec>
<sec id="s2-7-2">
<title>The Functional Analysis of Protein and Differentially Expressed Proteins</title>
<p>Gene Ontology (GO) and InterPro (IPR) analysis were conducted using the InterProScan-5 program against the nonredundant protein database (including Pfam, PRINTS, ProDom, SMART, ProSiteProfiles, and PANTHER) (<xref ref-type="bibr" rid="B16">Jones et&#x20;al., 2014</xref>); the databases of Clusters of Orthologous Groups (COG) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to analyze the protein family and pathway. The probable protein&#x2013;protein interactions (PPI) were predicted using the STRING-db server (<xref ref-type="bibr" rid="B11">Franceschini et&#x20;al., 2013</xref>) (<ext-link ext-link-type="uri" xlink:href="http://string.embl.de/">http://string.embl.de/</ext-link>). The enrichment pipeline was used for enrichment analysis of G.O, IPR, and KEGG (<xref ref-type="bibr" rid="B14">Huang et&#x20;al., 2009</xref>).</p>
</sec>
</sec>
<sec id="s2-8">
<title>Statistical Analysis</title>
<p>All data are presented as mean&#x20;&#xb1; standard error of the mean (SEM). Statistical analysis was performed by unpaired, two-tailed Students t-test using the GraphPad Prism 8.0 software (GraphPad Software) if not denoted otherwise. Differences were considered statistically significant at <italic>p</italic>-value &#x3c; 0.05. The Mann&#x2013;Whitney test statistically analyzed the protein quantitation results. Because &#x3e;two groups were compared in this survival study, the log-rank test with Bonferroni correction was used to compare two specific groups when the overall values were <italic>p</italic>&#x20;&#x3c; 0.05. Proteins were supposed to be significantly differentially expressed when the <italic>p</italic>-value &#x3c; 0.05, fold change (FC) &#x2264; 0.05 or <italic>p</italic>-value &#x3c; 0.05, FC &#x2265;&#x20;2.0.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Characterization of Neuroepithelial Transforming Gene 1 siRNA Nanoparticles</title>
<p>The obtained NET-1 siRNA nanoparticles were well dispersed in aqueous solution and appeared as quasi-spheres with nanosize by transmission electron microscopy observation (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>). The mean particle size of NET-1 siRNA nanoparticles was 675.1&#x20;&#xb1; 33.3&#xa0;nm, with a 0.341 mean polydispersity index (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>). Meanwhile, the zeta potential value of the complexes was &#x2013;38.58&#x20;&#xb1; 0.27&#xa0;mV (<xref ref-type="fig" rid="F1">Figure&#x20;1C</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Structure and characterization of NET-1 siRNA nanoparticles. <bold>(A)</bold> Transmission electron microscopy image showed a quasi-spherical morphology of NET-1 siRNA nanoparticles with a diameter of about 600&#xa0;nm. Original magnification, &#xd7;20,000. Scale bar, 500&#xa0;nm; <bold>(B)</bold> the DLS results showed a mean particle size of NET-1 siRNA nanoparticles to be 675.1&#x20;&#xb1; 33.3&#xa0;nm with a 0.341 polydispersity value; <bold>(C)</bold> the Zeta PALS BI-90 Plus analyzer indicated a surface zeta potential of NET-1 siRNA nanoparticles to be &#x2013;38.58&#x20;&#xb1; 0.27&#xa0;mV.</p>
</caption>
<graphic xlink:href="fmolb-08-678444-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Analysis of <italic>In Vivo</italic> Study</title>
<p>A decrease in tumor growth was observed in group C compared with other groups (<italic>p</italic>&#x20;&#x3d; 0.0461, <xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>). During the 60&#xa0;days follow-up, all mice with a tumor larger than 2&#xa0;cm were euthanized (according to the guidelines for Tumor Induction in Mice and Rats).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Tumor growth and mice survival in different mice groups. <bold>(A)</bold> Effect of the various treatments on tumor growth. <bold>(B)</bold> Effect of the various treatments on follow-up survival of mice (<italic>n</italic>&#x20;&#x3d; 6/group). Group A, blank control (black curve), group B, NET-1 siRNA nanoparticles without LIFU irradiation (blue curve); group C, NET-1 siRNA nanoparticles with LIFU irradiation (red curve); group D, NC-siRNA duplex nanoparticles with LIFU irradiation (brown curve); and group E, blank nanoparticles with LIFU irradiation (green curve).</p>
</caption>
<graphic xlink:href="fmolb-08-678444-g002.tif"/>
</fig>
<p>Briefly, of group A, three mice died a natural death and three mice were euthanized within 45&#xa0;days, the median survival was 28&#xa0;days (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>, black). Of group B, 4 mice died a natural death within 35&#xa0;days (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>, blue), and the other 2 mice were euthanized owing to the tumor size (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>, blue). Of group D, all mice died within 49&#xa0;days (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>, brown). Of group E, all mice died within 50&#xa0;days (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>, green).</p>
<p>Conversely, the group C showed the best survival result. 4 mice in group C survived until the end of follow-up (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>, red), and none of the tumors on any of the mice exceeded 20&#xa0;mm in any direction during the follow-up period (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>, red). The log-rank (Mantel&#x2013;Cox) test showed that the survival curves were significantly different (<italic>p</italic>&#x20;&#x3d; 0.0043).</p>
</sec>
<sec id="s3-3">
<title>Analysis of Immunohistochemical Staining</title>
<p>Massive positive immunostaining for NET-1 protein was observed in group A, group B, group D, and group E tissues (<xref ref-type="fig" rid="F3">Figures 3A&#x2013;E</xref>). However, the NET-1 protein expression was significantly downregulated in groups C compared with the other groups (<xref ref-type="fig" rid="F3">Figure&#x20;3C</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Example of the variability of IHC staining within tumor samples. <bold>(A)</bold> Group A showed strong staining, indicating the HCC cells surrounded by NET-1 protein (brown). <bold>(B)</bold> There was also an amount of NET-1 proteins around the tumor cells in group B. <bold>(C)</bold> There was little brown staining around the tumor, which indicated the NET-1 protein was significantly inhibited in group C. <bold>(D</bold>, <bold>E)</bold> There were also a large number of NET-1 proteins around tumor cells in group D and group E. <bold>(F)</bold> Quantitative IHC analysis of all groups, original magnification, &#xd7;400, Scale bar, 50&#xa0;&#xb5;m.</p>
</caption>
<graphic xlink:href="fmolb-08-678444-g003.tif"/>
</fig>
<p>The percentage of positive cells was quantified by ImageJ.&#x20;Quantitative IHC analysis indicated that the NET-1 protein staining was 56.11&#x20;&#xb1; 1.37 (group A), 51.69&#x20;&#xb1; 2.01 (group B), 22.24&#x20;&#xb1; 2.81 (group C), 53.29&#x20;&#xb1; 1.23 (group D), and 52.07&#x20;&#xb1; 0.24 (group E) compared with the whole picture in each group (<xref ref-type="fig" rid="F3">Figure&#x20;3F</xref>, <italic>p</italic>&#x20;&#x3c; 0.01, one-way ANOVA).</p>
</sec>
<sec id="s3-4">
<title>Analysis of Protein Abundance</title>
<p>Inspired by the IHC results, we carried out a label-free proteome analysis using FFPE HCC xenograft samples. In total, 3,389 proteins were quantified from the label-free analysis. Compared to Group A, a total of 78 proteins were differentially expressed (<italic>p</italic>-value &#x2264; 0.05, <xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>). Among them, the expression of 17 proteins were significantly upregulated (FC &#x2265; 2.0, <italic>p</italic>-value &#x2264; 0.05) and the manifestation of 61 proteins were significantly downregulated (FC &#x2264; 0.05, <italic>p</italic>-value &#x2264; 0.05). Cluster analysis of protein abundance was shown by a heat map (<xref ref-type="fig" rid="F4">Figure&#x20;4B</xref>). Red indicates high expression proteins and blue indicates low expression proteins.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Illustration of DEP quantified from the label-free analysis <bold>(A)</bold> Volcano plots of protein abundance between group A and group C. Green dots represent downregulated protein (FC &#x2264; 0.05, <italic>p</italic>-value&#x2264;0.05), and red dots represent upregulated protein (FC &#x2265; 2.0, <italic>p</italic>-value&#x2264;0.05). <bold>(B)</bold> Heat map of hierarchical clustering of DEP. Red indicates high expression protein, and blue indicates low expression protein.</p>
</caption>
<graphic xlink:href="fmolb-08-678444-g004.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>Analysis of Gene Ontology Functional Enrichment</title>
<p>Based on the G.O. enrichment analysis, we can explore the main biological functions of DEP. The representative five enriched G.O. details of DEP were shown in <xref ref-type="table" rid="T1">Table&#x20;1</xref>. The top 20 G.O. enrichment terms of DEP were illustrated in <xref ref-type="fig" rid="F5">Figure&#x20;5</xref>. The vast majority of G.O. enrichment terms belong to the biological process (B.P.). The enriched G.O. terms of the biological process were exhibited in detail in directed acyclic graph (DAG), as shown in <xref ref-type="sec" rid="s10">Supplementary Figure S1A</xref>. Besides, the enriched G.O. terms of molecular function (M.F.) and cellular component (CC) were shown in <xref ref-type="sec" rid="s10">Supplementary Figure S1B,C</xref>, respectively. The complete result of G.O. enrichment analysis was shown in <xref ref-type="sec" rid="s10">Supplementary Table S2</xref>. The top 10 G.O. enrichment terms were presented graphically by DAG (<xref ref-type="sec" rid="s10">Supplementary Figure&#x20;S1</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Representative five enriched G.O.&#x20;terms.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">G.O. ID</th>
<th align="center">G.O. term</th>
<th align="center">G.O. class</th>
<th align="center">
<italic>p</italic> value</th>
<th align="center">Protein ID</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">G.O.:0006468</td>
<td align="left">Protein phosphorylation</td>
<td align="left">B.P.</td>
<td align="char" char=".">0.001063999</td>
<td align="left">Q00534, P27361, F8W6G1, A0A024QZY5, O14976, B4E2L0, P12931</td>
</tr>
<tr>
<td align="left">G.O.:0004672</td>
<td align="left">Protein kinase activity</td>
<td align="left">M.F.</td>
<td align="char" char=".">0.001220283</td>
<td align="left">Q00534, P27361, F8W6G1, A0A024QZY5 O14976, B4E2L0, P12931</td>
</tr>
<tr>
<td align="left">G.O.:0034329</td>
<td align="left">Cell junction assembly</td>
<td align="left">B.P.</td>
<td align="char" char=".">0.002098766</td>
<td align="left">A0A2R8Y5A3, P78357</td>
</tr>
<tr>
<td align="left">G.O.:0042803</td>
<td align="left">Protein homodimerization activity</td>
<td align="left">M.F.</td>
<td align="char" char=".">0.003455028</td>
<td align="left">B7Z9B1, B4DL07</td>
</tr>
<tr>
<td align="left">G.O.:0033270</td>
<td align="left">Paranode region of axon</td>
<td align="left">CC</td>
<td align="char" char=".">0.019097794</td>
<td align="left">P78357</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>CC represents cellular component, M.F. represents molecular function, B.P. represents biological process.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Illustration of the top 20&#xa0;G.O. enrichment terms of all DEP. There are three categories of G..O. enrichment terms, biological process (B.P.), molecular function (M.F.), and cellular component (CC). The most DEP enriched in biological process (dark red), and only two CC terms had DEP enriched (purple). There were nine terms of MF (orange) were enriched by DEP.</p>
</caption>
<graphic xlink:href="fmolb-08-678444-g005.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>Analysis of Kyoto Encyclopedia of Genes and Genomes Pathway Enrichment</title>
<p>The dominant biochemical metabolic pathways and signal transduction pathways, which were regulated by DEP, could be identified by KEGG pathway enrichment analysis. The representative five enriched KEGG pathways of DEP were &#x201c;glutamatergic synapse,&#x201d; &#x201c;endocrine resistance,&#x201d; &#x201c;GABAergic synapse,&#x201d; &#x201c;gap junction,&#x201d; and &#x201c;melanogenesis&#x201d; (<xref ref-type="table" rid="T2">Table&#x20;2</xref>). The top 20 enriched KEGG pathway terms were presented by a scatter plot (<xref ref-type="fig" rid="F6">Figure&#x20;6</xref>). The details of all KEGG pathway enrichment analysis were shown in <xref ref-type="sec" rid="s10">Supplementary Table&#x20;S3</xref>.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Representative five enriched KEGG pathway terms of DEP.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Map ID</th>
<th align="center">Map title</th>
<th align="center">
<italic>p</italic> value</th>
<th align="center">Protein ID</th>
<th align="center">Description</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">map04724</td>
<td align="left">Glutamatergic synapse</td>
<td align="char" char=".">0.000434861</td>
<td align="left">A0A024R056, P27361, B4E2L0, Q5U0L9</td>
<td align="left">Guanine nucleotide binding protein (G protein), beta polypeptide 1, isoform CRA a, mitogen-activated protein kinase 3, cDNA FLJ54730, highly similar to cAMP-dependent protein kinase, beta-2-catalytic subunit, homer homolog 3 (Drosophila)</td>
</tr>
<tr>
<td align="left">map01522</td>
<td align="left">Endocrine resistance</td>
<td align="char" char=".">0.001179526</td>
<td align="left">P27361, P42773 B4E2L0, P12931</td>
<td align="left">Mitogen-activated protein kinase 3,Cyclin-dependent kinase 4 inhibitor C, cDNA FLJ54730, highly similar to cAMP-dependent protein kinase, beta-2-catalytic subunit, proto-oncogene tyrosine-protein kinase Src</td>
</tr>
<tr>
<td align="left">map04727</td>
<td align="left">GABAergic synapse</td>
<td align="char" char=".">0.001725647</td>
<td align="left">A0A024R056, B4E2L0 P12931</td>
<td align="left">Guanine nucleotide binding protein (G protein), beta polypeptide 1, isoform CRA a, cDNA FLJ54730, highly similar to cAMP-dependent protein kinase, beta-2-catalytic subunit, proto-oncogene tyrosine-protein kinase Src</td>
</tr>
<tr>
<td align="left">map04540</td>
<td align="left">Gap junction</td>
<td align="char" char=".">0.001771527</td>
<td align="left">P04350, P27361 B4E2L0, P12931</td>
<td align="left">Tubulin beta-4A chain, mitogen-activated protein kinase 3, cDNA FLJ54730, highly similar to cAMP-dependent protein kinase, beta-2-catalytic subunit, proto-oncogene tyrosine-protein kinase Src</td>
</tr>
<tr>
<td align="left">map04916</td>
<td align="left">Melanogenesis</td>
<td align="char" char=".">0.003105093</td>
<td align="left">A0A2R8Y5A3, P27361 B4E2L0</td>
<td align="left">Catenin beta-1, mitogen-activated protein kinase 3, cDNA FLJ54730, highly similar to cAMP-dependent protein kinase, beta-2-catalytic subunit</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>KEGG pathway enrichment analysis of DEP. The top 20 KEGG enrichment terms of all DEP between group A and group C were&#x20;shown in the scatter plot. The color of the dot represents the &#x2212;log10 (<italic>p</italic>-value), and the size of the dot represents the number of DEP.</p>
</caption>
<graphic xlink:href="fmolb-08-678444-g006.tif"/>
</fig>
</sec>
<sec id="s3-7">
<title>Analysis of InterPro Enrichment</title>
<p>In this study, we identified 47 IPR terms with differential enrichment (<xref ref-type="sec" rid="s10">Supplementary Table S4</xref>). The representative five enriched IPR IDs and titles of DEP were shown in <xref ref-type="table" rid="T3">Table&#x20;3</xref>. The top 20 enriched IPR terms were explained in <xref ref-type="fig" rid="F7">Figure&#x20;7</xref>. The details of all IPR enrichment terms were explained in <xref ref-type="sec" rid="s10">Supplementary Table&#x20;S4</xref>.</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Representative five enriched IPR terms of DEP.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">IPR ID</th>
<th align="center">IPR title</th>
<th align="center">
<italic>p</italic> value</th>
<th align="center">Protein ID</th>
<th align="center">Description</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">IPR001393</td>
<td align="left">Calsequestrin</td>
<td align="char" char=".">0.012354152</td>
<td align="left">P31415</td>
<td align="left">Calsequestrin-1</td>
</tr>
<tr>
<td align="left">IPR002495</td>
<td align="left">Glycosyl transferase, family 8</td>
<td align="char" char=".">0.012354152</td>
<td align="left">B2R5R5</td>
<td align="left">cDNA, FLJ92583, highly similar to homo sapiens glycogenin (GYG), mRNA</td>
</tr>
<tr>
<td align="left">IPR003109</td>
<td align="left">GoLoco motif</td>
<td align="char" char=".">0.012354152</td>
<td align="left">A0A0A0MRC4</td>
<td align="left">G-protein-signaling modulator 1</td>
</tr>
<tr>
<td align="left">IPR003585</td>
<td align="left">Neurexin/syndecan/glycophorin C</td>
<td align="char" char=".">0.012354152</td>
<td align="left">P78357</td>
<td align="left">Contactin-associated protein 1</td>
</tr>
<tr>
<td align="left">IPR004134</td>
<td align="left">Peptidase C1B, bleomycin hydrolase</td>
<td align="char" char=".">0.012354152</td>
<td align="left">Q13867</td>
<td align="left">Bleomycin hydrolase</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>IPR enrichment analysis. A total of 47 IPR terms were identified between group A and group C. The top 20 IPR enrichment terms of all DEP were shown in the bar plot. Each IPR terms has only one DEP enriched.</p>
</caption>
<graphic xlink:href="fmolb-08-678444-g007.tif"/>
</fig>
</sec>
<sec id="s3-8">
<title>Protein&#x2013;Protein Interaction Analysis</title>
<p>PPI analysis indicated that the significantly upregulated proteins P12931, A0A2R8Y5A3, Q00534, and P27361 and the significant downregulated proteins P31415, A0A024QZY5, B7Z9B1, B4DL07, and A8K335 were interrelated and interacted with each other (<xref ref-type="fig" rid="F8">Figure&#x20;8</xref>).</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>An interaction network of PPI analysis. The network revealed the direct and potential regulatory relationships between DEP. The downregulated proteins are represented by red nodes. The upregulated proteins are represented by blue nodes. Blue arrow indicates the Q86V21 (AACS) protein. Red arrow indicates the Q00534 (cyclin-dependent kinase 6) protein.</p>
</caption>
<graphic xlink:href="fmolb-08-678444-g008.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In our previous study, the NET-1 protein functions of HCC were investigated <italic>in vivo</italic> (<xref ref-type="bibr" rid="B41">Wu et&#x20;al., 2019</xref>). The expression of NET-1 protein in HCC xenograft was merely detected by IHC staining. In the present study, we hypothesized that the combination of NET-1 siRNA nanoparticles system and SDT could effectively inhibit the expression of NET-1 protein and regulate multiple proteins. Compared with preexisting combined anticancer strategies, this established strategy of nanoparticles system integrated with SDT offers distinct advantages, such as high penetration, noninvasive, and flexible choice of tumor site. The obtained nanoparticles could be employed as gene vehicle and cavitation nuclei for acoustic cavitation effect with SDT, which could dig holes of approximately 300&#xa0;nm on the tumor cell membranes (<xref ref-type="bibr" rid="B24">Meng et&#x20;al., 2019</xref>). The acoustic cavitation effect has minimal harmful influences on adjacent tissues or organs and is depicted to be a potential strategy for gene delivery (<xref ref-type="bibr" rid="B25">Miansari et&#x20;al., 2019</xref>). Also, as evidenced by IHC staining, the expression of NET-1 protein in group C was significantly depressed (<xref ref-type="fig" rid="F3">Figure&#x20;3</xref>).</p>
<p>Label-free proteome analysis was conducted to identify the protein abundance. Surprisingly, a total of 78 DEP were sifted from 3,389 quantified proteins (<italic>p</italic>-value&#x2264;0.05). Moreover, 17 proteins were significantly upregulated (green dots in <xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>, FC &#x2265; 2.0, <italic>p</italic>-value &#x2264; 0.05), such as Q86V21, which was described as acetoacetyl-CoA synthetase (AACS). AACS is highly expressed in the brain. It is a ketone body-utilizing enzyme for the synthesis of cholesterol and fatty acids, which are essential, abundant components of neuronal tissue. It has been proved that AACS is regulated by SREBP-2 and involves in the normal development of neurons (<xref ref-type="bibr" rid="B13">Hasegawa et&#x20;al., 2012</xref>). In contrast, 61 proteins were significantly downregulated (red dots in <xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>, FC &#x2264; 0.05, <italic>p</italic>-value &#x2264; 0.05), such as Q00534, which was described as cyclin-dependent kinase 6 (CDK6). Amplification of CDK6 and overexpression of cyclin D protein are also frequent in human cancers (<xref ref-type="bibr" rid="B2">Beroukhim et&#x20;al., 2010</xref>). The expression of CDK6 can be downregulated as a result of NET-1 protein depression, which provides a therapeutic potential for targeting CDK6 in the treatment of cancer. Our hypothesis was confirmed preliminarily. Encouraged by the proof-of-concept results, we analyzed the potential functions of DEP based on the mass spectra proteome analysis results.</p>
<p>First, G.O. enrichment analysis for biological process, cell component, and molecular function was performed. A total of 78 G.O. enrichment terms belong to the biological process, which would indicate that most of the DEP was involved in regulating the biological process of HCC. On the other hand, NET-1 protein was a member of the tetraspanin family, which was is a crucial point of HCC biological processes such as proliferation, differentiation, migration, and invasion (<xref ref-type="bibr" rid="B21">Mazzocca et&#x20;al., 2008</xref>; <xref ref-type="bibr" rid="B22">Mazzocca et&#x20;al., 2014</xref>). Consequently, silencing the NET-1 gene could regulate many HCC biological processes by depressing the NET-1 protein expression. Second, KEGG pathway enrichment analysis was performed to explore the pathways, which may be regulated by the NET-1 gene. A total of 45 significantly enriched pathways were identified (<italic>p</italic>-value &#x2264; 0.05), as shown in <xref ref-type="sec" rid="s10">Supplementary Table S3</xref>. In organisms, different proteins coordinate their biological behaviors, and the pathway-based analysis helps to understand their biological functions further. Interestingly, the DEP enriched in multifarious pathways, not only cancer-related pathways but also many other pathways, such as &#x201c;olfactory transduction&#x201d; (map04740), &#x201c;cocaine addiction&#x201d; (map05030), &#x201c;morphine addiction&#x201d; (map05032), &#x201c;Kaposi&#x2019;s sarcoma-associated herpesvirus infection&#x201d; (map05167), and &#x201c;human papillomavirus infection&#x201d; (map05165). We concluded that the function of the NET-1 gene is not only to regulate HCC but also to participate in a variety of biochemical metabolic pathways in the human body. Third, proteins are composed of IPR that are units of protein structure, function, and evolution. The study of the IPR of proteins is essential for understanding the biological role of proteins and their development. In this study, 47 IPR enrichment terms were found, as shown in <xref ref-type="sec" rid="s10">Supplementary Table S4</xref> (<italic>p</italic>-value &#x2264; 0.05). Each IPR had a specific protein corresponding to it. It could be proved that IPR can form new proteins by copying and combining. The combination distribution between different IPR does not conform to the random model but shows that some IPR has a powerful combination ability, some of which are rarely combined with other domains. Finally, PPI analysis revealed the direct and potential regulatory relationships between DEP. As shown in <xref ref-type="fig" rid="F8">Figure&#x20;8</xref>, all DEP formed a big circle and each node represented a DEP. The upregulated proteins are represented by blue nodes and the downregulated proteins are represented by red nodes. The interactions of DEP are incredibly sophisticated. All the protein&#x2013;protein interactions happened after the NET-1 gene has been silenced. For instance, the Q86V21 (AACS) protein (blue arrow in <xref ref-type="fig" rid="F8">Figure&#x20;8</xref>) could regulate the A0A024R5F7 protein, which was described as 7-dehydrocholesterol reductase isoform 1. It also indirectly proves that NET-1 protein could regulate the synthesis of cholesterol by modulating AACS and 7-dehydrocholesterol reductase isoform 1. The Q00534 (cyclin-dependent kinase 6) protein (red arrow in <xref ref-type="fig" rid="F8">Figure&#x20;8</xref>) could regulate the other 11 proteins, such as O60884 (DNAJA2), O14976 (GAK) and so on. GAK is a cellular serine/threonine kinase that plays a major role in clathrin-mediated membrane trafficking (<xref ref-type="bibr" rid="B38">Wouters et&#x20;al., 2019</xref>). It has been proved that osteosarcoma cell proliferation and survival are dependent on GAK (<xref ref-type="bibr" rid="B33">Susa et&#x20;al., 2010</xref>). Thus, the NET-1 protein may be a potential therapeutic target of osteosarcoma.</p>
<p>In summary, for the first time, our present study provides valuable insight into the regulation of NET-1 siRNA nanoparticles system and SDT on other proteins in HCC on a proteomics level. It proved that the NET-1 protein, one of the tetraspanin proteins, participated in regulating many critical signaling pathways in HCC development. Our results also provide a potential proposal for targeted therapy based on tetraspanin proteins to treat HCC, and further mechanism investigations are needed to reveal a more detailed mechanism of action for NET-1 protein regulation of&#x20;HCC.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD020763.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by Harbin Medical University.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>Conceptualization, WC and BW; Methodology, BW and HS; Data curation, XL and JL; Formal analysis, XL, YY, and HJ; Resources, BW and YC; Writing&#x2013;original draft, CW; Visualization, HJ and XL; Funding acquisition, WC, HS, XL, and BW; Supervision, WC and BW. All the authors contributed to the discussion during the whole project.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This research was supported by the National Natural Science Foundation of China (grant number 81873900), Natural Science Foundation of Heilongjiang Province (grant number YQ2020H037), Project of Health Commission of Heilongjiang Province (grant number 2019053), and HAI YAN Science Foundation of Harbin Medical University Cancer Hospital (grant number JJQN 2021-14 and JJMS 2021-30).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<ack>
<p>We thank Prof. Weiwei An and Prof. Yue Yang (Institute of Cancer Prevention and Treatment, Heilongjiang Academy of Medical Science) for supplying the altruistic guidance on the proteomic analyses.</p>
</ack>
<sec id="s10">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2021.678444/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmolb.2021.678444/full&#x23;supplementary-material</ext-link>.</p>
<supplementary-material xlink:href="Table2.XLSX" id="SM1" mimetype="application/XLSX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table4.XLS" id="SM2" mimetype="application/XLS" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table1.DOCX" id="SM3" mimetype="application/DOCX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table3.XLS" id="SM4" mimetype="application/XLS" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image1.TIF" id="SM5" mimetype="application/TIF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bass</surname>
<given-names>B. P.</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>K. B.</given-names>
</name>
<name>
<surname>Greytak</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>H. M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>A Review of Preanalytical Factors Affecting Molecular, Protein, and Morphological Analysis of Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue: How Well Do You Know Your FFPE Specimen?</article-title> <source>Arch. Pathol. Lab. Med.</source> <volume>138</volume> (<issue>11</issue>), <fpage>1520</fpage>&#x2013;<lpage>1530</lpage>. <comment>Epub 2014/10/31. PubMed PMID: 25357115</comment>. <pub-id pub-id-type="doi">10.5858/arpa.2013-0691-RA</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beroukhim</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mermel</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Raychaudhuri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Donovan</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>The Landscape of Somatic Copy-Number Alteration across Human Cancers</article-title>. <source>Nature</source> <volume>463</volume> (<issue>7283</issue>), <fpage>899</fpage>&#x2013;<lpage>905</lpage>. <comment>Epub 2010/02/19. PubMed PMID: 20164920; PubMed Central PMCID: PMCPMC2826709</comment>. <pub-id pub-id-type="doi">10.1038/nature08822</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broeckx</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Boonen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pringels</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sagaert</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Prenen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Landuyt</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Comparison of Multiple Protein Extraction Buffers for GeLC-MS/MS Proteomic Analysis of Liver and Colon Formalin-Fixed, Paraffin-Embedded Tissues</article-title>. <source>Mol. Biosyst.</source> <volume>12</volume> (<issue>2</issue>), <fpage>553</fpage>&#x2013;<lpage>565</lpage>. <comment>Epub 2015/12/18. PubMed PMID: 26676081</comment>. <pub-id pub-id-type="doi">10.1039/c5mb00670h</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>The Present and Future Role of Photodynamic Therapy in Cancer Treatment</article-title>. <source>Lancet Oncol.</source> <volume>5</volume> (<issue>8</issue>), <fpage>497</fpage>&#x2013;<lpage>508</lpage>. <comment>Epub 2004/08/04. PubMed PMID: 15288239</comment>. <pub-id pub-id-type="doi">10.1016/s1470-2045(04)01529-3</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castano</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Demidova</surname>
<given-names>T. N.</given-names>
</name>
<name>
<surname>Hamblin</surname>
<given-names>M. R.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Mechanisms in Photodynamic Therapy: Part One-Photosensitizers, Photochemistry and Cellular Localization</article-title>. <source>Photodiagnosis photodynamic Ther.</source> <volume>1</volume> (<issue>4</issue>), <fpage>279</fpage>&#x2013;<lpage>293</lpage>. <comment>Epub 2004/12/01. PubMed PMID: 25048432; PubMed Central PMCID: PMCPMC4108220</comment>. <pub-id pub-id-type="doi">10.1016/s1572-1000(05)00007-4</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaerkady</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Harsha</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Nalli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gucek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vivekanandan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Akhtar</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>A Quantitative Proteomic Approach for Identification of Potential Biomarkers in Hepatocellular Carcinoma</article-title>. <source>J.&#x20;Proteome Res.</source> <volume>7</volume> (<issue>10</issue>), <fpage>4289</fpage>&#x2013;<lpage>4298</lpage>. <comment>Epub 2008/08/22. PubMed PMID: 18715028; PubMed Central PMCID: PMCPMC3769105</comment>. <pub-id pub-id-type="doi">10.1021/pr800197z</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Takai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Miki</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Isolation of a Novel Oncogene, NET1, from Neuroepithelioma Cells by Expression cDNA Cloning</article-title>. <source>Oncogene</source> <volume>12</volume> (<issue>6</issue>), <fpage>1259</fpage>&#x2013;<lpage>1266</lpage>. <comment>Epub 1996/03/21. PubMed PMID: 8649828</comment> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Association of NET-1 Gene Expression with Human Hepatocellular Carcinoma</article-title>. <source>Int. J.&#x20;Surg. Pathol.</source> <volume>15</volume> (<issue>4</issue>), <fpage>346</fpage>&#x2013;<lpage>353</lpage>. <comment>Epub 2007/10/05. PubMed PMID: 17913940</comment>. <pub-id pub-id-type="doi">10.1177/1066896907306083</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrin</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>de la Mata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Montero-&#xc1;lvarez</surname>
<given-names>J.&#x20;L.</given-names>
</name>
<name>
<surname>Aguilar-Melero</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rodr&#xed;guez-Per&#xe1;lvarez</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Biomarkers for Hepatocellular Carcinoma: Diagnostic and Therapeutic Utility</article-title>. <source>Hmer</source> <volume>7</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. <comment>Epub 2015/05/01. PubMed PMID: 25926760; PubMed Central PMCID: PMCPMC4403743</comment>. <pub-id pub-id-type="doi">10.2147/hmer.S50161</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fowler</surname>
<given-names>C. B.</given-names>
</name>
<name>
<surname>O&#x27;Leary</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>J.&#x20;T.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Improving the Proteomic Analysis of Archival Tissue by Using Pressure-Assisted Protein Extraction: A Mechanistic Approach</article-title>. <source>J.&#x20;Proteomics Bioinform</source> <volume>7</volume> (<issue>6</issue>), <fpage>151</fpage>&#x2013;<lpage>157</lpage>. <comment>Epub 2014/07/23. PubMed PMID: 25049470; PubMed Central PMCID: PMCPMC4103194</comment>. <pub-id pub-id-type="doi">10.4172/jpb.1000315</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franceschini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Szklarczyk</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Frankild</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Simonovic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>STRING v9.1: Protein-Protein Interaction Networks, with Increased Coverage and Integration</article-title>. <source>Nucleic Acids Res.</source> <volume>41</volume> (<issue>Database issue</issue>), <fpage>D808</fpage>&#x2013;<lpage>D815</lpage>. <comment>Epub 2012/12/04. PubMed PMID: 23203871; PubMed Central PMCID: PMCPMC3531103</comment>. <pub-id pub-id-type="doi">10.1093/nar/gks1094</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma</article-title>. <source>Cell</source> <volume>179</volume> (<issue>2</issue>), <fpage>561</fpage>&#x2013;<lpage>577</lpage>. <comment>e22. Epub 2019/10/05. PubMed PMID: 31585088</comment>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.08.052</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hasegawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kume</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Iinuma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fukui</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Acetoacetyl-CoA Synthetase Is Essential for Normal Neuronal Development</article-title>. <source>Biochem. biophysical Res. Commun.</source> <volume>427</volume> (<issue>2</issue>), <fpage>398</fpage>&#x2013;<lpage>403</lpage>. <comment>Epub 2012/09/25. PubMed PMID: 23000407</comment>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2012.09.076</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Lempicki</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Bioinformatics Enrichment Tools: Paths toward the Comprehensive Functional Analysis of Large Gene Lists</article-title>. <source>Nucleic Acids Res.</source> <volume>37</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>13</lpage>. <comment>Epub 2008/11/27. PubMed PMID: 19033363; PubMed Central PMCID: PMCPMC2615629</comment>. <pub-id pub-id-type="doi">10.1093/nar/gkn923</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iglesias-Gato</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wikstr&#xf6;m</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tyanova</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lavallee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Thysell</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Carlsson</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>The Proteome of Primary Prostate Cancer</article-title>. <source>Eur. Urol.</source> <volume>69</volume> (<issue>5</issue>), <fpage>942</fpage>&#x2013;<lpage>952</lpage>. <comment>Epub 2015/12/15. PubMed PMID: 26651926</comment>. <pub-id pub-id-type="doi">10.1016/j.eururo.2015.10.053</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Binns</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>H.-Y.</given-names>
</name>
<name>
<surname>Fraser</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>McAnulla</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>InterProScan 5: Genome-Scale Protein Function Classification</article-title>. <source>Bioinformatics</source> <volume>30</volume> (<issue>9</issue>), <fpage>1236</fpage>&#x2013;<lpage>1240</lpage>. <comment>Epub 2014/01/24. PubMed PMID: 24451626; PubMed Central PMCID: PMCPMC3998142</comment>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btu031</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanetaka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lanza</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kanematsu</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2001</year>). <article-title>Overexpression of Tetraspanin CO-029 in Hepatocellular Carcinoma</article-title>. <source>J.&#x20;Hepatol.</source> <volume>35</volume> (<issue>5</issue>), <fpage>637</fpage>&#x2013;<lpage>642</lpage>. <comment>Epub 2001/11/03. PubMed PMID: 11690710</comment>. <pub-id pub-id-type="doi">10.1016/s0168-8278(01)00183-0</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Conley</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H. L.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Whole-Transcriptome Profiling of Formalin-Fixed, Paraffin-Embedded Renal Cell Carcinoma by RNA-Seq</article-title>. <source>BMC genomics</source> <volume>15</volume>, <fpage>1087</fpage>. <comment>Epub 2014/12/17. PubMed PMID: 25495041; PubMed Central PMCID: PMCPMC4298956</comment>. <pub-id pub-id-type="doi">10.1186/1471-2164-15-1087</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantsiou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Makridakis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fasoulakis</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Katafigiotis</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Constantinides</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Zoidakis</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Proteomics Analysis of Formalin Fixed Paraffin Embedded Tissues in the Investigation of Prostate Cancer</article-title>. <source>J.&#x20;Proteome Res.</source> <volume>19</volume>, <fpage>2631</fpage>&#x2013;<lpage>2642</lpage>. <comment>Epub 2019/11/05. PubMed PMID: 31682457</comment>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.9b00587</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martelotto</surname>
<given-names>L. G.</given-names>
</name>
<name>
<surname>Baslan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kendall</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Geyer</surname>
<given-names>F. C.</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Spraggon</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Whole-genome Single-Cell Copy Number Profiling from Formalin-Fixed Paraffin-Embedded Samples</article-title>. <source>Nat. Med.</source> <volume>23</volume> (<issue>3</issue>), <fpage>376</fpage>&#x2013;<lpage>385</lpage>. <comment>Epub 2017/02/07. PubMed PMID: 28165479; PubMed Central PMCID: PMCPMC5608257</comment>. <pub-id pub-id-type="doi">10.1038/nm.4279</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazzocca</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liotta</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Carloni</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Tetraspanin CD81-Regulated Cell Motility Plays a Critical Role in Intrahepatic Metastasis of Hepatocellular Carcinoma</article-title>. <source>Gastroenterology</source> <volume>135</volume> (<issue>1</issue>), <fpage>244</fpage>&#x2013;<lpage>256</lpage>. <comment>e1. Epub 2008/05/10. PubMed PMID: 18466772</comment>. <pub-id pub-id-type="doi">10.1053/j.gastro.2008.03.024</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazzocca</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tahmasebi Birgani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sabb&#xe0;</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Carloni</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Tetraspanin-enriched Microdomains and Hepatocellular Carcinoma Progression</article-title>. <source>Cancer Lett.</source> <volume>351</volume> (<issue>1</issue>), <fpage>23</fpage>&#x2013;<lpage>29</lpage>. <comment>Epub 2014/05/27. PubMed PMID: 24858024</comment>. <pub-id pub-id-type="doi">10.1016/j.canlet.2014.05.016</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McHale</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Callan</surname>
<given-names>J.&#x20;F.</given-names>
</name>
<name>
<surname>Nomikou</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fowley</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Callan</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Sonodynamic Therapy: Concept, Mechanism and Application to Cancer Treatment</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>880</volume>, <fpage>429</fpage>&#x2013;<lpage>450</lpage>. <comment>Epub 2015/10/22. PubMed PMID: 26486350</comment>. <pub-id pub-id-type="doi">10.1007/978-3-319-22536-4_22</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Sonoporation of Cells by a Parallel Stable Cavitation Microbubble Array</article-title>. <source>Adv. Sci.</source> <volume>6</volume> (<issue>17</issue>), <fpage>1900557</fpage>. <comment>Epub 2019/09/12. PubMed PMID: 31508275; PubMed Central PMCID: PMCPMC6724477</comment>. <pub-id pub-id-type="doi">10.1002/advs.201900557</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miansari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Schilling</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Kurashina</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Friend</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Inducing Mild Traumatic Brain Injury in <italic>C. elegans</italic> via Cavitation-free Surface Acoustic Wave-Driven Ultrasonic Irradiation</article-title>. <source>Sci. Rep.</source> <volume>9</volume> (<issue>1</issue>), <fpage>12775</fpage>. <comment>Epub 2019/09/06. PubMed PMID: 31485018; PubMed Central PMCID: PMCPMC6726767</comment>. <pub-id pub-id-type="doi">10.1038/s41598-019-47295-1</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murray</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Horgan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Macmathuna</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Doran</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>NET1-mediated RhoA Activation Facilitates Lysophosphatidic Acid-Induced Cell Migration and Invasion in Gastric Cancer</article-title>. <source>Br. J.&#x20;Cancer</source> <volume>99</volume> (<issue>8</issue>), <fpage>1322</fpage>&#x2013;<lpage>1329</lpage>. <comment>Epub 2008/10/02. PubMed PMID: 18827818; PubMed Central PMCID: PMCPMC2570507</comment>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6604688</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenthal</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sostaric</surname>
<given-names>J.&#x20;Z.</given-names>
</name>
<name>
<surname>Riesz</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Sonodynamic Therapy-Aa Review of the Synergistic Effects of Drugs and Ultrasound</article-title>. <source>Ultrason. Sonochem.</source> <volume>11</volume> (<issue>6</issue>), <fpage>349</fpage>&#x2013;<lpage>363</lpage>. <comment>Epub 2004/08/11. PubMed PMID: 15302020</comment>. <pub-id pub-id-type="doi">10.1016/j.ultsonch.2004.03.004</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serru</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dessen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Boucheix</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rubinstein</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Sequence and Expression of Seven New Tetraspans</article-title>. <source>Biochim. Biophys. Acta (Bba) - Protein Struct. Mol. Enzymol.</source> <volume>1478</volume> (<issue>1</issue>), <fpage>159</fpage>&#x2013;<lpage>163</lpage>. <comment>Epub 2000/03/17. PubMed PMID: 10719184</comment>. <pub-id pub-id-type="doi">10.1016/s0167-4838(00)00022-4</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Evaluation of Therapeutic Effect of Targeting Nanobubbles Conjugated with NET-1 siRNA by Shear Wave Elastography: an In Vivo Study of Hepatocellular Carcinoma Bearing Mice Model</article-title>. <source>Drug Deliv.</source> <volume>26</volume> (<issue>1</issue>), <fpage>944</fpage>&#x2013;<lpage>951</lpage>. <comment>Epub 2019/09/24. PubMed PMID: 31544556</comment>. <pub-id pub-id-type="doi">10.1080/10717544.2019.1667450</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>S.-Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nakao</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Expression and Clinical Significance of NET-1 and PCNA in Hepatocellular Carcinoma</article-title>. <source>Med. Oncol.</source> <volume>25</volume> (<issue>3</issue>), <fpage>341</fpage>&#x2013;<lpage>345</lpage>. <comment>Epub 2008/01/25. PubMed PMID: 18214716</comment>. <pub-id pub-id-type="doi">10.1007/s12032-008-9042-6</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Key</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Kalra</surname>
<given-names>K. L.</given-names>
</name>
</person-group> (<year>1991</year>). <article-title>Antigen Retrieval in Formalin-Fixed, Paraffin-Embedded Tissues: an Enhancement Method for Immunohistochemical Staining Based on Microwave Oven Heating of Tissue Sections</article-title>. <source>J.&#x20;Histochem. Cytochem.</source> <volume>39</volume> (<issue>6</issue>), <fpage>741</fpage>&#x2013;<lpage>748</lpage>. <comment>Epub 1991/06/01. PubMed PMID: 1709656</comment>. <pub-id pub-id-type="doi">10.1177/39.6.1709656</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shibaguchi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tsuru</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kuroki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kuroki</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Sonodynamic Cancer Therapy: a Non-invasive and Repeatable Approach Using Low-Intensity Ultrasound with a Sonosensitizer</article-title>. <source>Anticancer Res.</source> <volume>31</volume> (<issue>7</issue>), <fpage>2425</fpage>&#x2013;<lpage>2429</lpage>. <comment>Epub 2011/08/30. PubMed PMID: 21873154</comment> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Susa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Choy</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Schwab</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hornicek</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Mankin</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Cyclin G-Associated Kinase Is Necessary for Osteosarcoma Cell Proliferation and Receptor Trafficking</article-title>. <source>Mol. Cancer Ther.</source> <volume>9</volume> (<issue>12</issue>), <fpage>3342</fpage>&#x2013;<lpage>3350</lpage>. <comment>Epub 2010/10/01. PubMed PMID: 20881269</comment>. <pub-id pub-id-type="doi">10.1158/1535-7163.Mct-10-0637</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tachibana</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Feril</surname>
<given-names>L. B.</given-names>
</name>
<name>
<surname>Ikeda-Dantsuji</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Sonodynamic Therapy</article-title>. <source>Ultrasonics</source> <volume>48</volume> (<issue>4</issue>), <fpage>253</fpage>&#x2013;<lpage>259</lpage>. <comment>Epub 2008/04/25. PubMed PMID: 18433819</comment>. <pub-id pub-id-type="doi">10.1016/j.ultras.2008.02.003</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Allen</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Wagle</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Stojanov</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Perrin</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Cibulskis</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Marlow</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Whole-exome Sequencing and Clinical Interpretation of Formalin-Fixed, Paraffin-Embedded Tumor Samples to Guide Precision Cancer Medicine</article-title>. <source>Nat. Med.</source> <volume>20</volume> (<issue>6</issue>), <fpage>682</fpage>&#x2013;<lpage>688</lpage>. <comment>Epub 2014/05/20. PubMed PMID: 24836576; PubMed Central PMCID: PMCPMC4048335</comment>. <pub-id pub-id-type="doi">10.1038/nm.3559</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villanueva</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Hepatocellular Carcinoma</article-title>. <source>N. Engl. J.&#x20;Med.</source> <volume>380</volume> (<issue>15</issue>), <fpage>1450</fpage>&#x2013;<lpage>1462</lpage>. <comment>PubMed PMID: 30970190</comment>. <pub-id pub-id-type="doi">10.1056/NEJMra1713263</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wakabayashi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yoshihara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Masuda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tsukahara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sugiyama</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ishihama</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Phosphoproteome Analysis of Formalin-Fixed and Paraffin-Embedded Tissue Sections Mounted on Microscope Slides</article-title>. <source>J.&#x20;Proteome Res.</source> <volume>13</volume> (<issue>2</issue>), <fpage>915</fpage>&#x2013;<lpage>924</lpage>. <comment>Epub 2013/12/18. PubMed PMID: 24328109</comment>. <pub-id pub-id-type="doi">10.1021/pr400960r</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wouters</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pu</surname>
<given-names>S.-Y.</given-names>
</name>
<name>
<surname>Froeyen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lescrinier</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Einav</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Herdewijn</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Cyclin G-Associated Kinase (GAK) Affinity and Antiviral Activity Studies of a Series of 3-C-Substituted Isothiazolo[4,3-B]pyridines</article-title>. <source>Eur. J.&#x20;Med. Chem.</source> <volume>163</volume>, <fpage>256</fpage>&#x2013;<lpage>265</lpage>. <comment>Epub 2018/12/12. PubMed PMID: 30529544</comment>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2018.11.065</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Targeted Nanobubbles in Low-Frequency Ultrasound-Mediated Gene Transfection and Growth Inhibition of Hepatocellular Carcinoma Cells</article-title>. <source>Tumor Biol.</source> <volume>37</volume> (<issue>9</issue>), <fpage>12113</fpage>&#x2013;<lpage>12121</lpage>. <comment>PubMed PMID: 27216880</comment>. <pub-id pub-id-type="doi">10.1007/s13277-016-5082-2</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Preparation of Novel Targeting Nanobubbles Conjugated with Small Interfering RNA for Concurrent Molecular Imaging and Gene Therapy In Vivo</article-title>. <source>FASEB J.</source> <volume>33</volume>, <fpage>14129</fpage>&#x2013;<lpage>14136</lpage>. <comment>Epub 2019/10/29. PubMed PMID: 31657628</comment>. <pub-id pub-id-type="doi">10.1096/fj.201900716RR</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Structure of LINC00511&#x2010;siRNA&#x2010;conjugated Nanobubbles and Improvement of Cisplatin Sensitivity on Triple Negative Breast Cancer</article-title>. <source>FASEB j.</source> <volume>34</volume>, <fpage>9713</fpage>&#x2013;<lpage>9726</lpage>. <comment>Epub 2020/06/05. PubMed PMID: 32497336</comment>. <pub-id pub-id-type="doi">10.1096/fj.202000481R</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.-Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.-L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.-X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.-M.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Inhibition of Hepatocellular Carcinoma Growth and Angiogenesis by Dual Silencing of NET-1 and VEGF</article-title>. <source>J.&#x20;Mol. Hist.</source> <volume>44</volume> (<issue>4</issue>), <fpage>433</fpage>&#x2013;<lpage>445</lpage>. <comment>Epub 2013/05/03. PubMed PMID: 23636606</comment>. <pub-id pub-id-type="doi">10.1007/s10735-012-9480-5</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Quantitative Proteomics Reveals the Regulatory Networks of Circular RNA CDR1as in Hepatocellular Carcinoma Cells</article-title>. <source>J.&#x20;Proteome Res.</source> <volume>16</volume> (<issue>10</issue>), <fpage>3891</fpage>&#x2013;<lpage>3902</lpage>. <comment>Epub 2017/09/12. PubMed PMID: 28892615</comment>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.7b00519</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Prognostic Significance of Neuroepithelial Transforming Protein 1 in Hepatocellular Carcinoma</article-title>. <source>J.&#x20;Invest. Surg.</source> <volume>23</volume> (<issue>3</issue>), <fpage>163</fpage>&#x2013;<lpage>169</lpage>. <comment>Epub 2010/07/02. PubMed PMID: 20590388</comment>. <pub-id pub-id-type="doi">10.3109/08941939.2010.481010</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yumita</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Iwase</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nishi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Komatsu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Onodera</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Involvement of Reactive Oxygen Species in Sonodynamically Induced Apoptosis Using a Novel Porphyrin Derivative</article-title>. <source>Theranostics</source> <volume>2</volume> (<issue>9</issue>), <fpage>880</fpage>&#x2013;<lpage>888</lpage>. <comment>Epub 2012/10/20. PubMed PMID: 23082100; PubMed Central PMCID: PMCPMC3475214</comment>. <pub-id pub-id-type="doi">10.7150/thno.3899</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yumita</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nishigaki</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Umemura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Umemura</surname>
<given-names>S. I.</given-names>
</name>
</person-group> (<year>1989</year>). <article-title>Hematoporphyrin as a Sensitizer of Cell-Damaging Effect of Ultrasound</article-title>. <source>Jpn. J.&#x20;Cancer Res. : Gann</source> <volume>80</volume> (<issue>3</issue>), <fpage>219</fpage>&#x2013;<lpage>222</lpage>. <comment>Epub 1989/03/01. PubMed PMID: 2470713; PubMed Central PMCID: PMCPMC5917717</comment>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.1989.tb02295.x</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yumita</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Okudaira</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Momose</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Umemura</surname>
<given-names>S.-i.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Sonodynamically Induced Apoptosis and Active Oxygen Generation by Gallium-Porphyrin Complex, ATX-70</article-title>. <source>Cancer Chemother. Pharmacol.</source> <volume>66</volume> (<issue>6</issue>), <fpage>1071</fpage>&#x2013;<lpage>1078</lpage>. <comment>Epub 2010/03/06. PubMed PMID: 20204369</comment>. <pub-id pub-id-type="doi">10.1007/s00280-010-1264-6</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>